U.S. flag

An official website of the United States government

NM_000314.8(PTEN):c.737C>T (p.Pro246Leu) AND Hereditary cancer-predisposing syndrome

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Apr 11, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000131292.9

Allele description [Variation Report for NM_000314.8(PTEN):c.737C>T (p.Pro246Leu)]

NM_000314.8(PTEN):c.737C>T (p.Pro246Leu)

Gene:
PTEN:phosphatase and tensin homolog [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
10q23.31
Genomic location:
Preferred name:
NM_000314.8(PTEN):c.737C>T (p.Pro246Leu)
Other names:
p.P246L:CCG>CTG; NM_000314.6(PTEN):c.737C>T(p.Pro246Leu)
HGVS:
  • NC_000010.11:g.87957955C>T
  • NG_007466.2:g.99517C>T
  • NM_000314.8:c.737C>TMANE SELECT
  • NM_001304717.5:c.1256C>T
  • NM_001304718.2:c.146C>T
  • NP_000305.3:p.Pro246Leu
  • NP_001291646.4:p.Pro419Leu
  • NP_001291647.1:p.Pro49Leu
  • LRG_311t1:c.737C>T
  • LRG_311:g.99517C>T
  • NC_000010.10:g.89717712C>T
  • NM_000314.4:c.737C>T
  • NM_000314.5:c.737C>T
  • NM_000314.6:c.737C>T
  • P60484:p.Pro246Leu
  • p.P246L
Protein change:
P246L
Links:
UniProtKB: P60484#VAR_008740; dbSNP: rs587782350
NCBI 1000 Genomes Browser:
rs587782350
Molecular consequence:
  • NM_000314.8:c.737C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001304717.5:c.1256C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001304718.2:c.146C>T - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Hereditary cancer-predisposing syndrome
Synonyms:
Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000186263Ambry Genetics
criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)
Pathogenic
(Apr 11, 2024)
germlineclinical testing

PubMed (6)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway.

Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, Dasouki M, Feldman GL, Greenberg LA, Ivanovich J, Matloff E, Patterson A, Pierpont ME, Russo D, Nassif NT, Eng C.

Am J Hum Genet. 2003 Aug;73(2):404-11. Epub 2003 Jul 3.

PubMed [citation]
PMID:
12844284
PMCID:
PMC1180378

In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN.

Andrés-Pons A, Rodríguez-Escudero I, Gil A, Blanco A, Vega A, Molina M, Pulido R, Cid VJ.

Cancer Res. 2007 Oct 15;67(20):9731-9.

PubMed [citation]
PMID:
17942903
See all PubMed Citations (6)

Details of each submission

From Ambry Genetics, SCV000186263.10

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (6)

Description

The c.737C>T (p.P246L) alteration is located in exon 7 (coding exon 7) of the PTEN gene. This alteration results from a C to T substitution at nucleotide position 737, causing the proline (P) at amino acid position 246 to be replaced by a leucine (L). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant was reported as heterozygous in multiple individuals who met clinical criteria for PTEN hamartoma tumor syndrome, and was determined to be the result of a de novo mutation in one individual (Hobert, 2012; Vanderver, 2014; Shao, 2020). This amino acid position is highly conserved in available vertebrate species. This missense alteration is located in a region that has a low rate of benign missense variation (Lek, 2016; Firth, 2009). A yeast-based assay demonstrated that this alteration combined with another missense alteration failed to rescue yeast cells from p110alpha CAAX induced growth inhibition and release GFP-AKt1 from the cellular membrane, although both alterations by themselves had similar activity to wildtype. The authors postulated that this assay suggests patient-dependent loss of function effects (Andrés-Pons, 2007). In addition, p.P246L has been described as a pathogenic mutation leading to impaired PTEN protein levels and signaling in Lhermitte-Dulcose disease cells (Zhou, 2003). In another functional assay, this variant demonstrated low intracellular protein abundance on one multiplex functional assay (Matreyek, 2018). This alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Oct 20, 2024